MEK1/2 inhibitor withdrawal reverses acquired resistance driven by BRAFV600E amplification whereas KRASG13D amplification promotes EMT-chemoresistance
出版年份 2019 全文链接
标题
MEK1/2 inhibitor withdrawal reverses acquired resistance driven by BRAFV600E amplification whereas KRASG13D amplification promotes EMT-chemoresistance
作者
关键词
-
出版物
Nature Communications
Volume 10, Issue 1, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2019-05-02
DOI
10.1038/s41467-019-09438-w
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- KRAS Dimerization Impacts MEK Inhibitor Sensitivity and Oncogenic Activity of Mutant KRAS
- (2018) Chiara Ambrogio et al. CELL
- Control of cell death and mitochondrial fission by ERK1/2 MAP kinase signalling
- (2017) Simon J. Cook et al. FEBS Journal
- An approach to suppress the evolution of resistance in BRAFV600E-mutant cancer
- (2017) Yaohua Xue et al. NATURE MEDICINE
- Dual-specificity phosphatase 5 controls the localized inhibition, propagation, and transforming potential of ERK signaling
- (2017) Andrew M. Kidger et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Krasmutant genetically engineered mouse models of human cancers are genomically heterogeneous
- (2017) Wei-Jen Chung et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Exploiting Drug Addiction Mechanisms to Select against MAPKi-Resistant Melanoma
- (2017) Aayoung Hong et al. Cancer Discovery
- Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial
- (2016) Paolo A Ascierto et al. LANCET ONCOLOGY
- Different Facets of Copy Number Changes: Permanent, Transient, and Adaptive
- (2016) Sweta Mishra et al. MOLECULAR AND CELLULAR BIOLOGY
- Mouse models of colorectal cancer as preclinical models
- (2015) Rebecca E. McIntyre et al. BIOESSAYS
- Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial
- (2015) Georgina V Long et al. LANCET
- MCRIP1, an ERK Substrate, Mediates ERK-Induced Gene Silencing during Epithelial-Mesenchymal Transition by Regulating the Co-Repressor CtBP
- (2015) Kenji Ichikawa et al. MOLECULAR CELL
- Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer
- (2015) Xiaofeng Zheng et al. NATURE
- Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance
- (2015) Kari R. Fischer et al. NATURE
- A new role for the PI3K/Akt signaling pathway in the epithelial-mesenchymal transition
- (2015) Wenting Xu et al. Cell Adhesion & Migration
- Disruption of CRAF-Mediated MEK Activation Is Required for Effective MEK Inhibition in KRAS Mutant Tumors
- (2014) Piro Lito et al. CANCER CELL
- Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study
- (2014) Grant A McArthur et al. LANCET ONCOLOGY
- Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance
- (2013) Meghna Das Thakur et al. NATURE
- Concurrent MEK2 Mutation and BRAF Amplification Confer Resistance to BRAF and MEK Inhibitors in Melanoma
- (2013) Jessie Villanueva et al. Cell Reports
- The BH3 mimetic ABT-263 synergizes with the MEK1/2 inhibitor selumetinib/AZD6244 to promote BIM-dependent tumour cell death and inhibit acquired resistance
- (2012) Matthew J. Sale et al. BIOCHEMICAL JOURNAL
- ERK Inhibition Overcomes Acquired Resistance to MEK Inhibitors
- (2012) G. Hatzivassiliou et al. MOLECULAR CANCER THERAPEUTICS
- Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
- (2012) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mechanisms of acquired resistance to ERK1/2 pathway inhibitors
- (2012) A S Little et al. ONCOGENE
- Melanoma whole-exome sequencing identifies V600E B-RAF amplification-mediated acquired B-RAF inhibitor resistance
- (2012) Hubing Shi et al. Nature Communications
- Identification of the MEK1(F129L) Activating Mutation as a Potential Mechanism of Acquired Resistance to MEK Inhibition in Human Cancers Carrying the B-RafV600E Mutation
- (2011) H. Wang et al. CANCER RESEARCH
- Activation of the PIK3CA/AKT Pathway Suppresses Senescence Induced by an Activated RAS Oncogene to Promote Tumorigenesis
- (2011) Alyssa L. Kennedy et al. MOLECULAR CELL
- Oncogenic Ras-Induced Expression of Noxa and Beclin-1 Promotes Autophagic Cell Death and Limits Clonogenic Survival
- (2011) Mohamed Elgendy et al. MOLECULAR CELL
- RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
- (2011) Poulikos I. Poulikakos et al. NATURE
- Amplification of the Driving Oncogene, KRAS or BRAF, Underpins Acquired Resistance to MEK1/2 Inhibitors in Colorectal Cancer Cells
- (2011) A. S. Little et al. Science Signaling
- Activation of Forkhead Box O Transcription Factors by Oncogenic BRAF Promotes p21cip1-Dependent Senescence
- (2010) P. L. J. de Keizer et al. CANCER RESEARCH
- Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)
- (2010) J. R. Dry et al. CANCER RESEARCH
- ERK2 but Not ERK1 Induces Epithelial-to-Mesenchymal Transformation via DEF Motif-Dependent Signaling Events
- (2010) Sejeong Shin et al. MOLECULAR CELL
- RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
- (2010) Poulikos I. Poulikakos et al. NATURE
- COT drives resistance to RAF inhibition through MAP kinase pathway reactivation
- (2010) Cory M. Johannessen et al. NATURE
- Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
- (2010) Ramin Nazarian et al. NATURE
- An ERK-dependent pathway to Noxa expression regulates apoptosis by platinum-based chemotherapeutic drugs
- (2010) C Sheridan et al. ONCOGENE
- BRAF Gene Amplification Can Promote Acquired Resistance to MEK Inhibitors in Cancer Cells Harboring the BRAF V600E Mutation
- (2010) R. B. Corcoran et al. Science Signaling
- p57KIP2: "Kip"ing the Cell under Control
- (2009) I. S. Pateras et al. MOLECULAR CANCER RESEARCH
- Real-Time Quantitative RT-PCR: Design, Calculations, and Statistics
- (2009) I. Rieu et al. PLANT CELL
- MEK1 mutations confer resistance to MEK and B-RAF inhibition
- (2009) C. M. Emery et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Regulation of p57KIP2 during Muscle Differentiation: Role of Egr1, Sp1 and DNA Hypomethylation
- (2008) Rocco Figliola et al. JOURNAL OF MOLECULAR BIOLOGY
- Critical pathways in cellular senescence and immortalization revealed by gene expression profiling
- (2008) A L Fridman et al. ONCOGENE
- Senescence-Associated Secretory Phenotypes Reveal Cell-Nonautonomous Functions of Oncogenic RAS and the p53 Tumor Suppressor
- (2008) Jean-Philippe Coppé et al. PLOS BIOLOGY
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started